Woodline Partners’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $52.3M | Buy |
946,884
+49,185
| +5% | +$2.72M | 0.28% | 88 |
|
|
2025
Q1 | $43.4M | Buy |
897,699
+315,372
| +54% | +$15.3M | 0.28% | 103 |
|
|
2024
Q4 | $22.5M | Buy |
582,327
+115,809
| +25% | +$4.47M | 0.15% | 195 |
|
|
2024
Q3 | $21M | Sell |
466,518
-355,655
| -43% | -$16M | 0.18% | 185 |
|
|
2024
Q2 | $28.5M | Buy |
822,173
+185,217
| +29% | +$6.42M | 0.27% | 115 |
|
|
2024
Q1 | $18.4M | Buy |
+636,956
| New | +$18.4M | 0.17% | 182 |
|
|
2023
Q3 | – | Sell |
-427,264
| Closed | -$11.8M | – | 712 |
|
|
2023
Q2 | $11.8M | Sell |
427,264
-191,351
| -31% | -$5.29M | 0.14% | 184 |
|
|
2023
Q1 | $14.2M | Buy |
618,615
+106,475
| +21% | +$2.45M | 0.19% | 149 |
|
|
2022
Q4 | $5.59M | Buy |
+512,140
| New | +$5.59M | 0.07% | 294 |
|
|
2022
Q3 | – | Sell |
-388,637
| Closed | -$3.07M | – | 807 |
|
|
2022
Q2 | $3.07M | Sell |
388,637
-200,057
| -34% | -$1.58M | 0.05% | 326 |
|
|
2022
Q1 | $13.9M | Buy |
588,694
+95,707
| +19% | +$2.27M | 0.23% | 134 |
|
|
2021
Q4 | $16.9M | Buy |
+492,987
| New | +$16.9M | 0.24% | 120 |
|